Next Article in Journal
Automatic Infants’ Pain Assessment by Dynamic Facial Representation: Effects of Profile View, Gestational Age, Gender, and Race
Previous Article in Journal
Association between Urinary Calcium Excretion and Estimated Glomerular Filtration Rate Decline in Patients with Type 2 Diabetes Mellitus: A Retrospective Single-center Observational Study
Open AccessArticle

Tumor B7-H3 (CD276) Expression and Survival in Pancreatic Cancer

1
Division of Pathology, The Cancer Institute, Department of Pathology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan
2
Department of Hepato-Biliary-Pancreatic Surgery, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan
3
Biomarker Department, Daiichi Sankyo Co., Ltd., Tokyo 140-8710, Japan
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2018, 7(7), 172; https://doi.org/10.3390/jcm7070172
Received: 15 June 2018 / Revised: 5 July 2018 / Accepted: 8 July 2018 / Published: 10 July 2018
(This article belongs to the Section Molecular Diagnostics)
B7-H3 (CD276), a member of the family of immune modulators, orchestrates antitumor immunity. To date, only small-sized studies have examined the association of B7-H3 expression with survival in pancreatic cancer, yielding inconclusive results. We evaluated tumor B7-H3 expression in 150 consecutive patients with pancreatic ductal adenocarcinoma using immunohistochemistry. B7-H3 expression was positive (≥10% tumor cells) in 99 of 150 (66%) cases of pancreatic cancer. We classified the tumors into four groups depending on B7-H3 expression (negative, low, intermediate, and high) and found that higher B7-H3 expression was independently associated with lower disease-free survival (DFS; for high vs. negative B7-H3 expression: multivariable hazard ratio (HR) = 3.12; 95% confidence interval (CI) = 1.48–6.15; Ptrend = 0.0026). Furthermore, the association of B7-H3 expression with survival differed according to the pathological stage (p-stage) (Pinteraction = 0.048, between p-stages I–II and III–IV). The association of B7-H3 positivity with lower DFS was stronger in tumors with p-stage I–II (multivariable HR = 3.10, 95% CI = 1.75–5.69; P < 0.0001) than in those with p-stage III–IV (multivariable HR = 1.20, 95% CI = 0.67–2.28; P = 0.55). We demonstrated that tumor high B7-H3 expression is independently associated with poor survival in patients with pancreatic cancer and that this association is stronger in tumors with p-stage I–II than in those with p-stage III–IV. B7-H3 expression may be a useful prognostic biomarker for identifying aggressive early-stage pancreatic cancer. View Full-Text
Keywords: B7-H3; clinical outcome; immune checkpoint inhibitor; immune modulator; immunotherapy; pancreatic ductal adenocarcinoma; prognosis; tumor microenvironment B7-H3; clinical outcome; immune checkpoint inhibitor; immune modulator; immunotherapy; pancreatic ductal adenocarcinoma; prognosis; tumor microenvironment
Show Figures

Figure 1

MDPI and ACS Style

Inamura, K.; Takazawa, Y.; Inoue, Y.; Yokouchi, Y.; Kobayashi, M.; Saiura, A.; Shibutani, T.; Ishikawa, Y. Tumor B7-H3 (CD276) Expression and Survival in Pancreatic Cancer. J. Clin. Med. 2018, 7, 172.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop